Back to top
February 7, 2018
FDA grants breakthrough therapy designation for Dravet syndrome treatment
Research, Treatments, Pediatric Epilepsies

The FDA has granted Zogenix Inc. breakthrough therapy designation for low-dose fenfluramine use to treat seizures related to Dravet syndrome, according to a press release issued by the company.

“We are very pleased that the FDA has granted breakthrough therapy designation based on the efficacy and safety results from Study 1 reported in the fall of 2017,” Gail M. Farfel, PhD, chief development officer of Zogenix, said in the release. “We look forward to working closely with the FDA as we conclude our phase 3 clinical program in Dravet syndrome, a rare and catastrophic form of childhood epilepsy.

ZX008 can also be used for the treatment of Lennox-Gastaut syndrome, according to the release This form of epilepsy is also severe and begins in childhood. Those who have this condition are likely to also have intellectual disability.

Learn More

 

Related News

February 21, 2018
GW Pharmaceuticals Announces That Pipeline Compound...

GW Pharmaceuticals announced that a Phase 2a proof-of-concept study of a pipeline compound GWP42006 in adult patients with focal seizures did...

February 20, 2018
News from Abroad: Xenon Pharmaceuticals Advances Second...

Xenon Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901.

February 19, 2018
Maternal use of epilepsy drug may decrease school...

Pregnant women who used valproate had children with significantly lower school performance vs. children who were exposed to lamotrigine or not...